Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

This study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with EGFR-positive, CPS ≥ 1 resectable locally advanced head and neck squamous cell carcinoma .

NCT Number	NCT07524452
Lead Sponsor	Ming-Yuan Chen
Conditions	Locally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment	430 participants
Start Date	2026-02-06
Primary Completion	2031-02-28 (estimated)
Study Completion	2032-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-04-13